Bynfezia Pen
Bynfezia Pen is a somatostatin analog containing octreotide acetate. It mimics the actions of natural somatostatin to inhibit the secretion of various hormones, including growth hormone, insulin, glucagon, and gastrointestinal peptides. It is designed as a multi-dose prefilled pen for subcutaneous self-administration.
Dosage by Body Weight
Dosage is highly individualized and titrated based on clinical response, tolerability, and hormone levels. The typical starting dose for acromegaly is 50 mcg injected subcutaneously three times daily. For carcinoid tumors, the typical starting dose is 100 mcg to 600 mcg daily in 2 to 4 divided doses.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients. Octreotide is not routinely dosed by body weight.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients. Octreotide is not routinely dosed by body weight.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients. Octreotide is not routinely dosed by body weight.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients. Octreotide is not routinely dosed by body weight.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients. Octreotide is not routinely dosed by body weight.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients. Octreotide is not routinely dosed by body weight. |
| 5-7 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients. Octreotide is not routinely dosed by body weight. |
| 8-10 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients. Octreotide is not routinely dosed by body weight. |
| 11-15 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients. Octreotide is not routinely dosed by body weight. |
| 16-20 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients. Octreotide is not routinely dosed by body weight. |
Formulation
Purpose
Indicated for the reduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in patients with acromegaly. It is also used for the symptomatic treatment of severe diarrhea and flushing associated with metastatic carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas).
Generic Name
Octreotide acetateScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.